Abeona Therapeutics(ABEO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABEO Abeona Therapeutics

Closed 12-18 16:00:00 EST

4.92

+0.07

+1.44%

盘后4.92

+0.00+0.00%

19:53 EST

High4.93	Low4.81	Vol852.39K
Open4.88	D1 Closing4.85	Amplitude2.47%
Mkt Cap266.62M	Tradable Cap188.22M	Total Shares54.19M
T/O4.16M	T/O Rate2.23%	Tradable Shares38.26M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABEO","market":"US","secType":"STK","nameCN":"Abeona Therapeutics","latestPrice":4.92,"timestamp":1766091600000,"preClose":4.85,"halted":0,"volume":852394,"hourTrading":{"tag":"盘后","latestPrice":4.9199,"preClose":4.92,"latestTime":"19:53 EST","volume":5658,"amount":27837.064,"timestamp":1766105601046},"delay":0,"floatShares":38256000,"shares":54191361,"eps":1.286438,"marketStatus":"Closed","change":0.07,"latestTime":"12-18 16:00:00 EST","open":4.88,"high":4.93,"low":4.81,"amount":4160116.9295036,"amplitude":0.024742,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.286438,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":4.85,"preHourTrading":{"tag":"盘前","latestPrice":4.9,"preClose":4.85,"latestTime":"08:37 EST","volume":357,"amount":1749.0789099,"timestamp":1766065028633},"postHourTrading":{"tag":"盘后","latestPrice":4.9199,"preClose":4.92,"latestTime":"19:53 EST","volume":5658,"amount":27837.064,"timestamp":1766105601046},"volumeRatio":0.702725,"impliedVol":0.2366,"impliedVolPercentile":0.04},"requestUrl":"/m/hq/s/ABEO/tweets","defaultTab":"tweets","newsList":[{"id":"2591646617","title":"Abeona Therapeutics Appoints Mohamad Tabrizi as Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2591646617","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591646617?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:30","pubTimestamp":1765801817,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics Inc. has appointed Mohamad Tabrizi as Senior Vice President and Chief Business Officer. In this role, Tabrizi will lead corporate strategy, business development, and operational efficiency for the company. He joins Abeona from leadership positions in venture capital and previous roles in corporate development and investment banking.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abeona Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL3LlhM9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABEO","SG9999014013.SGD","SG9999014039.USD","BK4585","IE00BKPKM429.USD","LU2095319765.USD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014005.SGD","BK4139","IE00B64PRP62.GBP","BK4588","NDAQ","IE00BGHQF748.EUR","SG9999014021.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2591646501","title":"Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2591646501","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591646501?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:30","pubTimestamp":1765801800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA8YYVV4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABEO","BK4139"],"gpt_icon":0},{"id":"2590515872","title":"Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas","url":"https://stock-news.laohu8.com/highlight/detail?id=2590515872","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590515872?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:30","pubTimestamp":1765456200,"startTime":"0","endTime":"0","summary":"CLEVELAND, Dec.  11, 2025  (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in Galveston, Texas, as the newest Qu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203804/0/en/Abeona-Therapeutics-Announces-New-Qualified-Treatment-Center-for-ZEVASKYN-in-Texas.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABEO","BK4139"],"gpt_icon":0},{"id":"2589706330","title":"Abeona Therapeutics Treats First Patient With FDA-Approved ZEVASKYN Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2589706330","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589706330?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:30","pubTimestamp":1765197014,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics Inc. announced the first commercial patient treatment with ZEVASKYN , the first FDA-approved autologous gene therapy for wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa . ZEVASKYN uses a patient's own skin cells, genetically modified to produce functional type VII collagen, addressing the underlying cause of RDEB and promoting wound healing. The therapy demonstrated clinically meaningful wound healing and pain reduction after a single surgical application. The results were announced as part of the launch of commercial treatment, with additional patients scheduled for treatment in the near future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abeona Therapeutics Inc. published ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDLbw5BzX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABEO","IE00B3QW5Z07.USD","BK4585","BK4588","IE00BGHQF748.EUR","BK4139","SG9999014005.SGD","LU2210149790.SGD","SG9999014021.USD","BK4112","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","LU2095319765.USD","LU2210150020.SGD","NDAQ"],"gpt_icon":0},{"id":"2589330725","title":"Abeona Therapeutics® Announces First Patient Treatment With Zevaskyn® Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2589330725","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589330725?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:30","pubTimestamp":1765197000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA7M8PHP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABEO"],"gpt_icon":0},{"id":"2588023105","title":"ABEO Acquires 86.43% Stake in VOGO","url":"https://stock-news.laohu8.com/highlight/detail?id=2588023105","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588023105?lang=en_us&edition=fundamental","pubTime":"2025-12-04 01:18","pubTimestamp":1764782315,"startTime":"0","endTime":"0","summary":"ABEO now holds 86.43% of the share capital of VOGO following the successful completion of a public offer. This update was disclosed by VOGO.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vogo SA published the original content used to generate this news brief on December 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL8HdL3v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABEO","BK4139"],"gpt_icon":0},{"id":"2588772201","title":"Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588772201","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588772201?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:30","pubTimestamp":1764592201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2NJN2X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABEO"],"gpt_icon":0},{"id":"2588727836","title":"Press Release: Abeona Therapeutics(R) Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727836","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588727836?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:30","pubTimestamp":1764592200,"startTime":"0","endTime":"0","summary":"CLEVELAND, Dec. 01, 2025  -- Abeona Therapeutics Inc.  today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635.On November 30, 2025, the Compensation Committee of Abeona's Board of Directors granted restricted stock equity awards as a material inducement to employment to two individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 45,685 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee's continued employment with Abeona on the applicable vesting dates.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","BK4099","ABEO","BK4555","BK4585","BK4588","BK4232","03160","NQmain","R","BK4139","BK4022","BK4604"],"gpt_icon":0},{"id":"2583268403","title":"Director Mark Alvino Reports Sale of Abeona Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583268403","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583268403?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:36","pubTimestamp":1763156182,"startTime":"0","endTime":"0","summary":"Mark Alvino, a Director at Abeona Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abeona Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL1vRtPv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Mark Alvino Reports Sale of Abeona Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABEO"],"gpt_icon":0},{"id":"2583452561","title":"Optimistic Buy Rating for Abeona Therapeutics Amid Promising ZEVASKYN Outlook and Favorable Market Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2583452561","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583452561?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:35","pubTimestamp":1763033741,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on ABEO stock, giving a Buy rating yesterday. Ram Selvaraju has given his...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-abeona-therapeutics-amid-promising-zevaskyn-outlook-and-favorable-market-conditions-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-abeona-therapeutics-amid-promising-zevaskyn-outlook-and-favorable-market-conditions-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABEO"],"gpt_icon":0},{"id":"2583302624","title":"Abeona Therapeutics: Resilient Path to Profitability with Strong Market Demand and Strategic Optimizations","url":"https://stock-news.laohu8.com/highlight/detail?id=2583302624","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583302624?lang=en_us&edition=fundamental","pubTime":"2025-11-13 03:25","pubTimestamp":1762975532,"startTime":"0","endTime":"0","summary":"Stephen Willey, an analyst from Stifel Nicolaus, maintained the Buy rating on Abeona Therapeutics. The associated price target is $19.00. Stephen W...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/abeona-therapeutics-resilient-path-to-profitability-with-strong-market-demand-and-strategic-optimizations-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/abeona-therapeutics-resilient-path-to-profitability-with-strong-market-demand-and-strategic-optimizations-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ABEO"],"gpt_icon":0},{"id":"2583302671","title":"Abeona Therapeutics price target lowered to $19 from $20 at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2583302671","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583302671?lang=en_us&edition=fundamental","pubTime":"2025-11-13 03:20","pubTimestamp":1762975227,"startTime":"0","endTime":"0","summary":"Stifel analyst Stephen Willey lowered the firm’s price target on Abeona Therapeutics (ABEO) to $19 from $20 and keeps a Buy rating on the shares. M...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abeona-therapeutics-price-target-lowered-to-19-from-20-at-stifel-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abeona-therapeutics-price-target-lowered-to-19-from-20-at-stifel-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABEO","SF"],"gpt_icon":0},{"id":"2583730401","title":"Abeona Therapeutics Shares Soar on Higher Demand for Zevaskyn","url":"https://stock-news.laohu8.com/highlight/detail?id=2583730401","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583730401?lang=en_us&edition=fundamental","pubTime":"2025-11-13 03:16","pubTimestamp":1762974960,"startTime":"0","endTime":"0","summary":"Shares of Abeona Therapeutics were on the rise after the biotechnology company narrowed its quarterly loss and reported an uptick in patient demand for Zevaskyn, its gene therapy for wound treatment.The stock soared 22% to $5.12 a share in midday trading. Despite the intraday gains, shares remain down 9% year to date.\"Based on trends in patient demand, treatment-center expansion and market access, we're seeing growing patient demand for Zevaskyn,\" Abeona executives said on a call with analysts Wednesday. \"Despite the temporary delay in the first patient treatment, we are well positioned for our launch success in 2026.\". Food and Drug Administration-approved Zevaskyn is an autologous cell sheet-based gene therapy for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa, a rare skin disease. Abeona touts the treatment as the first of its kind.The number of identified eligible patients at qualified treatment centers who are motivated to initiate the treatmen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABEO"],"gpt_icon":0},{"id":"2582376102","title":"Abeona Therapeutics reports Q3 EPS (10c), consensus (34c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376102","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582376102?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:36","pubTimestamp":1762950964,"startTime":"0","endTime":"0","summary":"“We are scaling the ZEVASKYN launch to meet patient needs,” said Vish Seshadri, Chief Executive Officer of Abeona. “We have strong and growing pati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abeona-therapeutics-reports-q3-eps-10c-consensus-34c-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abeona-therapeutics-reports-q3-eps-10c-consensus-34c-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABEO"],"gpt_icon":0},{"id":"2582376194","title":"Abeona Therapeutics sees cash runway for over two years","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376194","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582376194?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:35","pubTimestamp":1762950951,"startTime":"0","endTime":"0","summary":"Cash, cash equivalents, restricted cash and short-term investments totaled $207.5 million as of September 30, 2025. The current cash position, with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abeona-therapeutics-sees-cash-runway-for-over-two-years-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abeona-therapeutics-sees-cash-runway-for-over-two-years-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ABEO"],"gpt_icon":0},{"id":"2582768053","title":"Abeona Therapeutics Q3 EPS $(0.10) Beats $(0.29) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582768053","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582768053?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:31","pubTimestamp":1762950669,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.29) by 65.52 percent. This is a 84.13 percent increase over losses of $(0.63) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48799517/abeona-therapeutics-q3-eps-0-10-beats-0-29-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABEO"],"gpt_icon":0},{"id":"2582376563","title":"Abeona Therapeutics Q3 EPS USD -0.1 VS. Ibes Estimate USD -0.29","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376563","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582376563?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:30","pubTimestamp":1762950602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX31FF66:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABEO"],"gpt_icon":0},{"id":"2582376353","title":"Abeona Therapeutics Q3 Income From Operations USD -24.018 Million VS. Ibes Estimate USD -18.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582376353?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:30","pubTimestamp":1762950602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX31FF66:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABEO"],"gpt_icon":0},{"id":"2582132376","title":"Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2582132376","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582132376?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:30","pubTimestamp":1762950600,"startTime":"0","endTime":"0","summary":"- First anticipated ZEVASKYN patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along with broad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/12/3186123/0/en/Abeona-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Corporate-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0545039389.USD","BK4139","BK4108","LU0553294199.USD","LU2637428348.USD","CMS","LU2500361329.USD","BK4211","LU0949170772.SGD","BK4588","BK4208","LU0661504455.SGD","BK4077","CHCO","LU1894683264.USD","LU2346227817.USD","LU0738911758.USD","LU1003077747.HKD","ABEO","EB","LU1894683348.USD"],"gpt_icon":0},{"id":"2582327400","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2582327400","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582327400?lang=en_us&edition=fundamental","pubTime":"2025-11-12 19:00","pubTimestamp":1762945200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·CI&T Inc. Class A                               3Q       .10        AMC. ·Digi Intl Inc.                                  4Q       .51    4:00 PM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CURI","CRMT","ALUR","ACXP","GUTS","CREX","CRMD","RSKD","MGX","AFYA","CLBT","ASND","BEEM","ABOS","CELC","AIRG","ALH","ARDT","AEMD","ANNX","CCAP","AKRO","CABA","CSCO","ATXS","AFCG","AUTL","CAAP","CPRT","ALVO","ABSI","BLDP","ABEO","ALC","IBTA","PYPD","AEBI","ALMS","AMAT","ATAT","AVBP","TWFG","CINT","IMRX","AYTU","LUNG","BABA","ARCO","ARX"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.abeonatherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1133},{"period":"1month","weight":0.0754},{"period":"3month","weight":-0.1401},{"period":"6month","weight":-0.1766},{"period":"1year","weight":-0.1752},{"period":"ytd","weight":-0.1293}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.1,"avgChangeRate":-0.109902},{"month":2,"riseRate":0.6,"avgChangeRate":0.122147},{"month":3,"riseRate":0.6,"avgChangeRate":0.002349},{"month":4,"riseRate":0.7,"avgChangeRate":0.022294},{"month":5,"riseRate":0.5,"avgChangeRate":-0.010507},{"month":6,"riseRate":0.3,"avgChangeRate":0.003162},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.015738},{"month":8,"riseRate":0.636364,"avgChangeRate":0.073309},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.009981},{"month":10,"riseRate":0.545455,"avgChangeRate":-0.003904},{"month":11,"riseRate":0.454545,"avgChangeRate":0.087228},{"month":12,"riseRate":0.090909,"avgChangeRate":-0.144977}],"exchange":"NASDAQ","name":"Abeona Therapeutics","nameEN":"Abeona Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Abeona Therapeutics(ABEO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Abeona Therapeutics(ABEO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Abeona Therapeutics,ABEO,Abeona Therapeutics股票,Abeona Therapeutics股票老虎,Abeona Therapeutics股票老虎国际,Abeona Therapeutics行情,Abeona Therapeutics股票行情,Abeona Therapeutics股价,Abeona Therapeutics股市,Abeona Therapeutics股票价格,Abeona Therapeutics股票交易,Abeona Therapeutics股票购买,Abeona Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Abeona Therapeutics(ABEO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Abeona Therapeutics(ABEO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction